The Science

KMO

at the interface between

inflammation, immunity and metabolism

Kynurenine monooxygenase (KMO) plays a major role in the regulation of inflammation and how the immune system is controlled by inflammation and metabolism. These conditions can be acute, for example critical illness or major surgery, or more long-standing, for example endometriosis and cancers that have evaded the immune system. All these scenarios have a pressing need for new medicines.

KMO inhibitors have the potential to revolutionise the care and outcomes of patients suffering from diseases where inflammation and metabolism meet immunity.

The founding team bring a deep understanding of clinical medicine, disease biology, kynurenine pathway biochemistry and structural biology of KMO, allied to expertise in medicines discovery.

Kynos Therapeutics is poised to bring a new generation of potent first-in-class KMO inhibitors to the market - ready to impact on unmet medical needs.

address OPERATIONAL HEADQUARTERS

Kynos Therapeutics Ltd.
Enterprise Hub 2.14
Murchison House
King's Buildings
10 Max Born Crescent
Edinburgh EH9 3BF
United Kingdom

get-in-touch

To contact Us ,

please use

the form

send
tnx-msg